BioVie Inc. Warrant

BioVie Inc. is a clinical-stage biopharmaceutical company that develops drug therapies for neurological and neurodegenerative disorders and advanced liver disease in the United States. Its lead candidate BIV201 is in Phase 3 for life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism. The company also develops Bezisterim, an investigational orally administered small molecule in Phase 3 for mild to moderate Alzheimer's disease, Phase 2b for Parkinson's disease, and a long COVID program. Formerly NanoAntibiotics, Inc., it changed its name to BioVie Inc. in July 2016, was incorporated in 2013, and is headquartered in Carson City, Nevada.